Boenning & Scattergood Initiates Coverage on Exelixis (EXEL) with a Neutral
More News related to EXEL
- Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
- Ligand Updates License Agreement with Exelixis
- Exelixis (EXEL) Tops Q3 EPS by 8c; Comments on Outlook
- Exelixis Announces Third Quarter 2009 Financial Results
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
Boenning & Scattergood initiates coverage on Exelixis (Nasdaq: EXEL) with a Neutral.
To see more analyst ratings on EXEL Click Here.
Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds.
Related Categories
New CoverageStocks Mentioned
+0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
